Expression of miR-152 in cervical cancer and its influence on cisplatin resistance

Abstract

Background: Cervical cancer has a high mortality rate.
 Aim: We aimed to study the expression of micro ribonucleic acid 152 (miR-152) in cervical cancer and its influence on cisplatin(DDP) resistance.
 Methodology: Cervical cancer Hela cells were divided into control, DDP, DDP + mimic nc and DDP + miR-152 mimic groups.
 Results: DDP, DDP + mimic nc and DDP + miR-152 mimic groups had lower cell survival rate, smaller number of single clones and cells penetrating the membrane, and higher apoptosis rate and miR-152 expression than those of the control group (P<0.05). Compared with DDP and DDP + mimic nc groups, the cell survival rate, number of single clones and number of cells penetrating the membrane significantly decreased, while the apoptosis rate and miR-152 expression increased in the DDP + miR-152 mimic group (P<0.05). ERBB3 was a downstream target gene of miR-152. Hela cells transfected with miR-152 mimic had lower protein expressions of Snail, ERBB3, Akt2, p-Akt and c-myc than those of NC cells (P<0.05).
 Conclusion: MiR-152 suppresses the proliferation, migration and infiltration of cervical cancer cells and reduces their resistanceto DDP chemotherapy by inhibiting the expressions of proteins in the ERBB3/Akt/c-myc and ERBB3/Akt/Snail pathways.
 Keywords: miR-152; cervical cancer; cisplatin; drug resistance.

Editor’s choice: Covid-19 and HIV are still very much with us

“…Putting infections aside we have other interesting papers. First cancer 27 – 35 . The cancer papers touch on cervical cancer 27 , ovarian tumors 28 , hematological malignancy; others 29 – 35 ; and surgery 36 – 49 .…”

“…First cancer 27 – 35 . The cancer papers touch on cervical cancer 27 , ovarian tumors 28 , hematological malignancy; others 29 – 35 ; and surgery 36 – 49 . These are followed by ocular conditions 50 – 54 .…”